GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks

GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks

Saved in:

Bibliographic Details
Main Authors:	Ioannis Ilias, Lina Zabuliene, Manfredi Rizzo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Clinical Diabetes and Healthcare
Subjects:	glucagon-like peptide-1 receptor agonists obesity weight loss diabetes adverse drug reaction pancreatitis
Online Access:	https://www.frontiersin.org/articles/10.3389/fcdhc.2024.1530811/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adverse effects of GLP – 1 Receptor Agonists
by: Anna Kasprzak, et al.
Published: (2025-02-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
by: Jian‐Yu Jhu, et al.
Published: (2025-02-01)

Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus
by: Mijin Kim, et al.
Published: (2025-01-01)

Managing cardiovascular events, hyperglycemia, and obesity in type 2 diabetes through microRNA regulation linked to glucagon-like peptide-1 receptor agonists
by: Xiaolei Miao, et al.
Published: (2025-01-01)

High fructose rewires gut glucose sensing via glucagon-like peptide 2 to impair metabolic regulation in mice
by: Eya Sellami, et al.
Published: (2025-03-01)

Incretin hormone agonists as promising antiobesity drugs - review of literature
by: Aleksandra Grzegorczyk, et al.
Published: (2025-01-01)

Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
by: Aaron King, et al.
Published: (2025-03-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review
by: Yao Wang, et al.
Published: (2024-06-01)

Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

Foundational contributions of Svetlana Mojsov to the GLP-1 field
by: George Barany, et al.
Published: (2024-10-01)

The protective role of GLP-1 in neuro-ophthalmology
by: Sohum Sheth, et al.
Published: (2023-08-01)

Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
by: Sho Furusawa, et al.
Published: (2024-06-01)

The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
by: Jonathan D. Douros, et al.
Published: (2025-02-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

Are obese rats influenced by GLP1 and IR through aerobic exercise? A case study
by: Ali Sayyah, et al.
Published: (2016-08-01)

Potential benefits of GLP-1 analogues and metformin in patients with osteoarthritis
by: Anna Skowronek, et al.
Published: (2025-01-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Obstructive sleep apnea, the NLRP3 inflammasome and the potential effects of incretin therapies
by: Michelle Wei, et al.
Published: (2025-01-01)

From Clinical Trial Evidence to Clinical Guidelines: Perspectives on REWIND from Clinicians in the Gulf and Levant Region
by: Talal Ashour, et al.
Published: (2023-11-01)

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta‐Analysis
by: Saixian Shi, et al.
Published: (2025-01-01)

[18F]FB(ePEG12)12-exendin-4 noninvasive imaging of insulinoma negative for insulin immunostaining on specimen from endoscopic ultrasonography-guided fine needle aspiration: a case report with review of literature
by: Daisuke Otani, et al.
Published: (2024-09-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β‐Klotho‐Mediated Ferroptosis Inhibition
by: Shasha Tian, et al.
Published: (2025-01-01)

Characterization of LY3324954 a long-acting glucagon-receptor agonist
by: William Roell, et al.
Published: (2025-01-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
by: Chenqi Lu, et al.
Published: (2024-12-01)

Appendicitis After Initiation of Tirzepatide
by: Chan G, et al.
Published: (2025-01-01)

Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma
by: Angela J. Yoon, et al.
Published: (2025-01-01)

Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer
by: Nan Niu, et al.
Published: (2025-01-01)

β-glucan attenuates intestinal ischemia-reperfusion injury in mice by promoting glucagon-like peptide-1 secretion
by: WANG Wei, et al.
Published: (2025-01-01)

Intestinal butyric acid-mediated disruption of gut hormone secretion and lipid metabolism in vasopressin receptor-deficient mice
by: Kazuki Harada, et al.
Published: (2025-01-01)

Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice
by: Marwa Al‐Badri, et al.
Published: (2025-01-01)

Modulation of stress-related behaviour by preproglucagon neurons and hypothalamic projections to the nucleus of the solitary tract
by: Marie K. Holt, et al.
Published: (2025-01-01)

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia
by: Paschalis Evangelidis, et al.
Published: (2025-01-01)

The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration
by: Chiara Cencioni, et al.
Published: (2025-01-01)

G Protein-Coupled Receptor 17 Inhibits Glucagon-like Peptide-1 Secretion via a Gi/o-Dependent Mechanism in Enteroendocrine Cells
by: Jason M. Conley, et al.
Published: (2024-12-01)

Phytocompounds from Indonesia Medicinal Herbs as Potential Apelin Receptor Agonist for Heart Failure Therapy: An In-silico Approach
by: Muhamad Rizqy Fadhillah, et al.
Published: (2025-01-01)

Narcolepsy treatment: from exorcism and bloodletting to modern therapy with histamine receptor inverse agonists
by: E. Sakalauskaitė-Juodeikienė, et al.
Published: (2020-09-01)